{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T09:10:19Z","timestamp":1720343419869},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13277-015-3772-9","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T20:13:03Z","timestamp":1437423183000},"page":"217-225","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia"],"prefix":"10.1007","volume":"37","author":[{"given":"Stefania","family":"Trino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Simeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Laurenzana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Caivano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"La Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pietrantuono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Bianchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitina","family":"Grieco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Signorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fragasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Bochicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Venturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cilloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"issue":"4","key":"3772_CR1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways. BCR-ABL Clin Cancer Res. 2012;18(4):930\u20137.","journal-title":"BCR-ABL Clin Cancer Res"},{"issue":"6","key":"3772_CR2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"3","key":"3772_CR3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3772_CR4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/leu.2008.337","volume":"23","author":"D Bruennert","year":"2009","unstructured":"Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, et al. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia. 2009;23(5):983\u20135.","journal-title":"Leukemia"},{"issue":"50","key":"3772_CR5","doi-asserted-by":"crossref","first-page":"31453","DOI":"10.1074\/jbc.272.50.31453","volume":"272","author":"R Wechsler-Reya","year":"1997","unstructured":"Wechsler-Reya R, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J Biol Chem. 1997;272(50):31453\u20138.","journal-title":"J Biol Chem"},{"issue":"5657","key":"3772_CR6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1126\/science.1092586","volume":"303","author":"BJ Peter","year":"2004","unstructured":"Peter BJ, Kent HM, Mills IG, Vallis Y, Butler PJ, Evans PR, et al. BAR domains as sensors of membrane curvature: the amphiphysin BAR structure. Science. 2004;303(5657):495\u20139.","journal-title":"Science"},{"issue":"3","key":"3772_CR7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.embor.7400105","volume":"5","author":"B Habermann","year":"2004","unstructured":"Habermann B. The BAR-domain family of proteins: a case of bending and binding? EMBO Rep. 2004;5(3):250\u20135.","journal-title":"EMBO Rep"},{"issue":"2","key":"3772_CR8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M","volume":"86","author":"K Ge","year":"2000","unstructured":"Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, et al. Loss of heterozygosity and tumor suppressor activity of BIN1 in prostate carcinoma. Int J Cancer. 2000;86(2):155\u201361.","journal-title":"Int J Cancer"},{"issue":"3","key":"3772_CR9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<376::AID-IJC14>3.0.CO;2-1","volume":"85","author":"K Ge","year":"2000","unstructured":"Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer. 2000;85(3):376\u201383.","journal-title":"Int J Cancer"},{"key":"3772_CR10","first-page":"862879","volume":"2012","author":"S Tanida","year":"2012","unstructured":"Tanida S, Mizoshita T, Ozeki K, Tsukamoto H, Kamiya T, Kataoka H, et al. Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol. 2012;2012:862879.","journal-title":"Int J Surg Oncol"},{"key":"3772_CR11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2119\/molmed.2011.00319","volume":"18","author":"K Pan","year":"2012","unstructured":"Pan K, Liang XT, Zhang HK, Zhao JJ, Wang DD, Li JJ, et al. Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med. 2012;18:507\u201318.","journal-title":"Mol Med"},{"issue":"41","key":"3772_CR12","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1038\/sj.onc.1203681","volume":"19","author":"K Elliott","year":"2000","unstructured":"Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein BIN1 activates a caspase-independent cell death program. Oncogene. 2000;19(41):4669\u201384.","journal-title":"Oncogene"},{"issue":"7","key":"3772_CR13","first-page":"3151","volume":"61","author":"JB DuHadaway","year":"2001","unstructured":"DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. BIN1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res. 2001;61(7):3151\u20136.","journal-title":"Cancer Res"},{"issue":"Pt 23","key":"3772_CR14","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1242\/jcs.113688","volume":"125","author":"K Balaji","year":"2012","unstructured":"Balaji K, Mooser C, Janson CM, Bliss JM, Hojjat H, Colicelli J. RIN1 orchestrates the activation of RAB5 GTPases and ABL tyrosine kinases to determine the fate of EGFR. J Cell Sci. 2012;125(Pt 23):5887\u201396.","journal-title":"J Cell Sci"},{"issue":"Pt 20","key":"3772_CR15","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1242\/jcs.00718","volume":"116","author":"H Kajiho","year":"2003","unstructured":"Kajiho H, Saito K, Tsujita K, Kontani K, Araki Y, Kurosu H, et al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. J Cell Sci. 2003;116(Pt 20):4159\u201368.","journal-title":"J Cell Sci"},{"issue":"9","key":"3772_CR16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cub.2005.03.049","volume":"15","author":"H Hu","year":"2005","unstructured":"Hu H, Bliss JM, Wang Y, Colicelli J. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol. 2005;15(9):815\u201323.","journal-title":"Curr Biol"},{"issue":"1","key":"3772_CR17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1534-5807(01)00008-9","volume":"1","author":"GG Tall","year":"2001","unstructured":"Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF. Ras-activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell. 2001;1(1):73\u201382.","journal-title":"Dev Cell"},{"issue":"10","key":"3772_CR18","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1128\/MCB.11.10.5016","volume":"11","author":"JP O'Bryan","year":"1991","unstructured":"O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991;11(10):5016\u201331.","journal-title":"Mol Cell Biol"},{"issue":"19","key":"3772_CR19","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","volume":"5","author":"H Axelrod","year":"2014","unstructured":"Axelrod H, Pienta KJ. Axl as a mediator of cellular growth and survival. Oncotarget. 2014;5(19):8818\u201352.","journal-title":"Oncotarget"},{"issue":"4","key":"3772_CR20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cytogfr.2006.04.004","volume":"17","author":"S Hafizi","year":"2006","unstructured":"Hafizi S, Dahlb\u00e4ck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 2006;17(4):295\u2013304.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"23","key":"3772_CR21","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1111\/j.1742-4658.2006.05529.x","volume":"273","author":"S Hafizi","year":"2006","unstructured":"Hafizi S, Dahlb\u00e4ck B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006;273(23):5231\u201344.","journal-title":"FEBS J"},{"issue":"11","key":"3772_CR22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.18632\/oncotarget.360","volume":"2","author":"M Dufies","year":"2011","unstructured":"Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2011;2(11):874\u201385.","journal-title":"Oncotarget"},{"issue":"14","key":"3772_CR23","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","volume":"122","author":"I Ben-Batalla","year":"2013","unstructured":"Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013;122(14):2443\u201352.","journal-title":"Blood"},{"issue":"10","key":"3772_CR24","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1158\/1535-7163.MCT-11-0116","volume":"10","author":"A Verma","year":"2011","unstructured":"Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer kinases in cancer. Mol Cancer Ther. 2011;10(10):1763\u201373.","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"3772_CR25","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.18632\/oncotarget.2542","volume":"5","author":"X Wu","year":"2014","unstructured":"Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014;5(20):9546\u201363.","journal-title":"Oncotarget"},{"key":"3772_CR26","doi-asserted-by":"crossref","unstructured":"Mahadevan D, Theiss N, Morales C, Stejskal AE, Cooke LS, Zhu M, et al. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget. 2014.","DOI":"10.18632\/oncotarget.3021"},{"issue":"10","key":"3772_CR27","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172\u20135.","journal-title":"Leukemia"},{"key":"3772_CR28","doi-asserted-by":"crossref","unstructured":"Arruga F, Messa F, Pradotto M, Bernardoni R, Bracco E, Carturan S, et al. Disabled gene is involved in CML progression and its expression level at diagnosis can predict major molecular response (MMR) to imatinib therapy. Cancer Res (Annual Meeting of the American Association for Cancer Research Abstract). 2010;70(Suppl 1).","DOI":"10.1158\/1538-7445.AM10-251"},{"key":"3772_CR29","first-page":"3470","volume":"114","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Pradotto M, Messa F, Arruga F, Bracco E, Carturan S, et al. Identification of Rab5 as a gene involved in chronic myeloid leukemia (CML) progression. Blood (ASH Annual Meeting Abstracts). 2009;114:3470.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"3772_CR30","doi-asserted-by":"crossref","first-page":"E973","DOI":"10.1152\/ajpendo.90857.2008","volume":"296","author":"JV Abella","year":"2009","unstructured":"Abella JV, Park M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metabol. 2009;296(5):E973\u201384.","journal-title":"Am J Physiol Endocrinol Metabol"},{"issue":"37","key":"3772_CR31","doi-asserted-by":"crossref","first-page":"21468","DOI":"10.1074\/jbc.270.37.21468","volume":"270","author":"R Jong de","year":"1995","unstructured":"de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem. 1995;270(37):21468\u201371.","journal-title":"J Biol Chem"},{"issue":"55","key":"3772_CR32","doi-asserted-by":"crossref","first-page":"8852","DOI":"10.1038\/sj.onc.1206892","volume":"22","author":"DM Dinulescu","year":"2003","unstructured":"Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, et al. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 2003;22(55):8852\u201360.","journal-title":"Oncogene"},{"issue":"5","key":"3772_CR33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00418-008-0401-3","volume":"129","author":"K Roepstorff","year":"2008","unstructured":"Roepstorff K, Grovdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008;129(5):563\u201378.","journal-title":"Histochem Cell Biol"},{"issue":"7","key":"3772_CR34","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","volume":"8","author":"S Grosso","year":"2009","unstructured":"Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther. 2009;8(7):1924\u201333.","journal-title":"Mol Cancer Ther"},{"key":"3772_CR35","doi-asserted-by":"crossref","unstructured":"Lu L, Saunders V, Kok CH, Leclercq T, Hughes TP, White DL. Modeling ponatinib resistance in BCR-ABL1+ cell lines: implications for Ponatinib resistance in TKI-resistant and TKI-na\u00efve patients. Blood (ASH Annual Meeting Abstracts). 2014;124(21).","DOI":"10.1182\/blood.V124.21.4515.4515"},{"issue":"8","key":"3772_CR36","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","volume":"118","author":"R Gioia","year":"2011","unstructured":"Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood. 2011;118(8):2211\u201321.","journal-title":"Blood"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3772-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3772-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T08:05:18Z","timestamp":1599293118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3772-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3772"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3772-9","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]}}}